Ekso Bionics Holdings Inc (EKSO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ekso Bionics Holdings Inc (EKSO) has a cash flow conversion efficiency ratio of -0.370x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.12 Million) by net assets ($5.74 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Ekso Bionics Holdings Inc worth for the company's overall valuation and market capitalisation.
Ekso Bionics Holdings Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Ekso Bionics Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Ekso Bionics Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ekso Bionics Holdings Inc ranked by their cash flow conversion efficiency. Explore earnings quality score of Ekso Bionics Holdings Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Winner Group Enterprise Public Company Limited
BK:WINNER
|
-0.097x |
|
Sinher Technology Inc
TW:4999
|
0.012x |
|
Hydrogene De France SA
PA:HDF
|
-0.075x |
|
Highlight Communications AG
XETRA:HLG
|
-26.847x |
|
Jetbest
TWO:4741
|
0.026x |
|
GiG Software PLC
ST:GIG-SDB
|
-0.014x |
|
Unlu Yatirim Holding AS
IS:UNLU
|
-0.041x |
|
Corline Biomedical AB
ST:CLBIO
|
0.001x |
Annual Cash Flow Conversion Efficiency for Ekso Bionics Holdings Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Ekso Bionics Holdings Inc from 2012 to 2025. View Ekso Bionics Holdings Inc share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $9.03 Million | $-11.80 Million | -1.307x | -68.72% |
| 2024-12-31 | $12.71 Million | $-9.85 Million | -0.775x | +18.97% |
| 2023-12-31 | $12.61 Million | $-12.05 Million | -0.956x | -65.63% |
| 2022-12-31 | $25.44 Million | $-14.69 Million | -0.577x | -92.61% |
| 2021-12-31 | $37.22 Million | $-11.16 Million | -0.300x | +84.82% |
| 2020-12-31 | $4.43 Million | $-8.76 Million | -1.975x | +14.91% |
| 2019-12-31 | $6.80 Million | $-15.77 Million | -2.320x | +71.44% |
| 2018-12-31 | $2.73 Million | $-22.16 Million | -8.125x | -456.59% |
| 2017-12-31 | $21.39 Million | $-31.23 Million | -1.460x | +61.86% |
| 2016-12-31 | $6.53 Million | $-25.00 Million | -3.827x | -84.53% |
| 2015-12-31 | $8.81 Million | $-18.27 Million | -2.074x | -215.12% |
| 2014-12-31 | $22.80 Million | $-15.01 Million | -0.658x | +17.39% |
| 2013-12-31 | $15.05K | $-11.99K | -0.797x | 0.00% |
| 2012-12-31 | $15.05K | $-11.99K | -0.797x | -- |
About Ekso Bionics Holdings Inc
Ekso Bionics Holdings, Inc. designs, develops, distributes, and commercializes exoskeleton products in the Americas, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company provides EksoNR, a wearable robotic exoskeleton; Ekso Indego Therapy, a powered exoskeleton; Ekso Indego Personal, a powered lower limb orthosis; and Ekso EVO, a wearable upper body exoskeleton. It … Read more